2. Academic Validation
  3. Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis

Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis

  • Sci Transl Med. 2023 Sep 27;15(715):eade3157. doi: 10.1126/scitranslmed.ade3157.
Meghan Mooring 1 2,  Grace A Yeung 2,  Panu Luukkonen 3,  Silvia Liu 4 5,  Muhammad Waqas Akbar 2,  Gary J Zhang 2,  Oluwashanu Balogun 1 4,  Xuemei Yu 6,  Rigen Mo 6,  Kari Nejak-Bowen 1 4 5,  Masha V Poyurovsky 6,  Carmen J Booth 7,  Liza Konnikova 8,  Gerald I Shulman 3 9,  Dean Yimlamai 1 2 5 10
Affiliations

Affiliations

  • 1 Department of Cellular and Molecular Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
  • 2 Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Yale School of Medicine, New Haven, CT 06514, USA.
  • 3 Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06514, USA.
  • 4 Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
  • 5 Pittsburgh Liver Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
  • 6 Kadmon Corporation LLC, 450 East 29th Street, New York, NY 10016, USA.
  • 7 Department of Comparative Medicine, Yale School of Medicine, New Haven, CT 06514, USA.
  • 8 Section of Neonatology, Department of Pediatrics, Yale School of Medicine, New Haven, CT 06514, USA.
  • 9 Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06514, USA.
  • 10 Yale Liver Center, Yale School of Medicine, New Haven, CT 06514, USA.
PMID: 37756381 DOI: 10.1126/scitranslmed.ade3157
Abstract

Obesity is increasing worldwide and leads to a multitude of metabolic diseases, including Cardiovascular Disease, type 2 diabetes, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis (NASH). Cysteine-rich angiogenic inducer 61 (CYR61) is associated with the progression of NASH, but it has been described to have anti- and proinflammatory properties. We sought to examine the role of liver CYR61 in NASH progression. CYR61 liver-specific knockout mice on a NASH diet showed improved glucose tolerance, decreased liver inflammation, and reduced fibrosis. CYR61 polarized infiltrating monocytes promoting a proinflammatory/profibrotic phenotype through an IRAK4/Syk/NF-κB signaling cascade. In vitro, CYR61 activated a profibrotic program, including PDGFa/PDGFb expression in macrophages, in an IRAK4/Syk/NF-κB-dependent manner. Furthermore, targeted-antibody blockade reduced CYR61-driven signaling in macrophages in vitro and in vivo, reducing fibrotic development. This study demonstrates that CYR61 is a key driver of liver inflammation and fibrosis in NASH.

Figures
Products